BR9800501A - Derivados de isoxazol e crotonamida e seu uso como produtos farmacêuticos e em diagnósticos. - Google Patents

Derivados de isoxazol e crotonamida e seu uso como produtos farmacêuticos e em diagnósticos.

Info

Publication number
BR9800501A
BR9800501A BR9800501-4A BR9800501A BR9800501A BR 9800501 A BR9800501 A BR 9800501A BR 9800501 A BR9800501 A BR 9800501A BR 9800501 A BR9800501 A BR 9800501A
Authority
BR
Brazil
Prior art keywords
formula
isoxazole
diagnostics
crotonamide
derivatives
Prior art date
Application number
BR9800501-4A
Other languages
English (en)
Other versions
BR9800501B1 (pt
Inventor
Stefan Dr Muellner
Bernd Dr Kirschbaum
Wilfried Dr Schwab
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of BR9800501A publication Critical patent/BR9800501A/pt
Publication of BR9800501B1 publication Critical patent/BR9800501B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE ISOXAZOL E CROTONAMIDA E SEU USO COMO PRODUTOS FARMACêUTICOS E EM DIAGNóSTICOS"<D>. Esta invenção refere-se a derivados de isoxazol e crotonamida e a seu uso como produtos farmacêuticos e em diagósticos. Um composto de fórmula (I), onde R^ 1^ é o radical de fórmula II ou III (II) (III) é adequado para a produção de um produto farmacêutico para o tratamento de inflamações, doenças carcinomatosas ou doenças autoimunes. Um compos de fórmula IV é adequado para a produção de anticorpos específicos contra o composto de fórmula I para a descoberta de proteínas de ligação específica provenientes de extratos de células, soro, sangue ou fluidos sinoviais, para a purificação de proteínas, para a modificação de placas de microtitulação ou para a preparação de material de cromatografia, em particular de material de cromotografia de afinidade, e para uso em diagnósticos.
BRPI9800501-4A 1997-01-28 1998-01-28 derivado de isoxazol e crotonamida e uso do mesmo. BR9800501B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19702988A DE19702988A1 (de) 1997-01-28 1997-01-28 Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika

Publications (2)

Publication Number Publication Date
BR9800501A true BR9800501A (pt) 1999-12-07
BR9800501B1 BR9800501B1 (pt) 2010-05-18

Family

ID=7818547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9800501-4A BR9800501B1 (pt) 1997-01-28 1998-01-28 derivado de isoxazol e crotonamida e uso do mesmo.

Country Status (19)

Country Link
US (3) US5977151A (pt)
EP (1) EP0859000B1 (pt)
JP (1) JP4163776B2 (pt)
KR (1) KR100572808B1 (pt)
CN (1) CN1120160C (pt)
AR (1) AR010399A1 (pt)
AT (1) ATE231495T1 (pt)
AU (1) AU729750B2 (pt)
BR (1) BR9800501B1 (pt)
CA (1) CA2228060C (pt)
CZ (1) CZ296122B6 (pt)
DE (2) DE19702988A1 (pt)
DK (1) DK0859000T3 (pt)
ES (1) ES2189010T3 (pt)
HU (1) HUP9800147A3 (pt)
PL (1) PL194932B1 (pt)
PT (1) PT859000E (pt)
RU (1) RU2192421C2 (pt)
TR (1) TR199800117A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7157283B2 (en) * 2002-08-02 2007-01-02 3M Innovative Properties Company Continuous process for the production of combinatorial libraries of modified materials
US7632916B2 (en) * 2002-08-02 2009-12-15 3M Innovative Properties Company Process to modify polymeric materials and resulting compositions
US7125902B2 (en) * 2004-05-28 2006-10-24 Unitech Pharmaceuticals, Inc. Methods, compounds, and diagnostics for cancer treatment
JP2008526877A (ja) * 2005-01-05 2008-07-24 エージェンコート パーソナル ジェノミクス 可逆的ヌクレオチドターミネーターおよびその使用
ES2614931T3 (es) * 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
US20080085912A1 (en) * 2006-10-06 2008-04-10 Unitech Pharmaceuticals, Inc. Isoxazole derivatives and methods of treating diseases
US20100213060A1 (en) * 2009-02-23 2010-08-26 Bio-Rad Laboratories, Inc. Aqueous transfer buffer
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
ES2619557T3 (es) 2009-05-04 2017-06-26 Agios Pharmaceuticals, Inc. Activadores de PKM2 para uso en el tratamiento del cáncer
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
WO2020189676A1 (ja) * 2019-03-19 2020-09-24 三井化学株式会社 プロピレン系樹脂組成物、成形体およびプロピレン重合体
EP4537112A1 (en) * 2022-06-13 2025-04-16 YeeFan Med Inc Methods for detecting b-isox precipitates or captured proteins as biofluid biomarkers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
ES2102367T3 (es) * 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
US5744664A (en) * 1990-07-05 1998-04-28 Hoechst Aktiengesellschaft Cycloolefin copolymers (COCS) as substrate material for liquid-crystal displays
DE59203828D1 (de) * 1991-10-23 1995-11-02 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft.
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
ATE154526T1 (de) * 1992-04-16 1997-07-15 Merck Patent Gmbh Aktivierte trägermaterialien, ihre herstellung und verwendung
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same

Also Published As

Publication number Publication date
TR199800117A3 (tr) 1998-08-21
US5977151A (en) 1999-11-02
KR100572808B1 (ko) 2006-10-13
HK1009813A1 (en) 1999-06-11
DE59806965D1 (de) 2003-02-27
CZ24998A3 (cs) 1998-08-12
DK0859000T3 (da) 2003-05-12
PT859000E (pt) 2003-06-30
EP0859000A1 (de) 1998-08-19
JPH10231279A (ja) 1998-09-02
KR19980070841A (ko) 1998-10-26
US6265588B1 (en) 2001-07-24
AR010399A1 (es) 2000-06-07
DE19702988A1 (de) 1998-07-30
CN1189491A (zh) 1998-08-05
HU9800147D0 (en) 1998-03-30
CZ296122B6 (cs) 2006-01-11
MX9800757A (es) 1998-10-31
AU5274898A (en) 1998-07-30
JP4163776B2 (ja) 2008-10-08
AU729750B2 (en) 2001-02-08
RU2192421C2 (ru) 2002-11-10
CA2228060C (en) 2008-01-08
PL324549A1 (en) 1998-08-03
EP0859000B1 (de) 2003-01-22
US6121479A (en) 2000-09-19
HUP9800147A3 (en) 1999-01-28
BR9800501B1 (pt) 2010-05-18
TR199800117A2 (xx) 1998-08-21
ES2189010T3 (es) 2003-07-01
HUP9800147A1 (hu) 1998-07-28
PL194932B1 (pl) 2007-07-31
CN1120160C (zh) 2003-09-03
ATE231495T1 (de) 2003-02-15
CA2228060A1 (en) 1998-07-28

Similar Documents

Publication Publication Date Title
CA2228060A1 (en) Isoxazole and crotonamide derivatives and their use as pharmaceuticals and diagnostics
Vishwanath et al. Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities
Conroy et al. Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187
Hashimoto et al. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.
IE861543L (en) IgE-BF
BR9611400A (pt) &#34;agentes antimicobiano de benzoxazina&#34;.
EP0610445A1 (en) Compositions comprising a bactericidal/permeability increasing protein and a lipid carrier, methods of making same, and uses thereof
Bhosale et al. Molecular docking studies, synthesis, toxicological evaluation using brine shrimp (Artemia salina L.) model and anti-inflammatory activity of some N-(substituted)-5-phenyl-1, 3, 4-thiadiazol-2-amine derivatives
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
Hawiger et al. Endotoxin-sensitive membrane component of human platelets
TW261615B (pt)
BR0012610A (pt) Novo derivado de difenilpiperidina
Pidgeon et al. Antiviral phospholipids. Anti-HIV drugs conjugated to the glycerobackbone of phospholipids.
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
BR9804720A (pt) Sistema de expressão controlado por vìrus ou oncogene.
Banerjee et al. Mucin binding mitogenic lectin from freshwater Indian gastropod Belamyia bengalensis: purification and molecular characterization
Pangburn Spontaneous thioester bond formation in α2-macroglobulin, C3 and C4
Gamaniel et al. Anti-sickling, analgesic and anti-inflammatory properties of 3, 5-dimethoxy-4-hydroxy benzoic acid and 2, 3, 4-trihydroxyacetophenone
US4393055A (en) Hydroxyalkyl ether derivatives of rutin poly(H-)sulfate and method of use
CA2173338A1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives
JP3420582B2 (ja) 新規レクチン様物質
RU2141968C1 (ru) Способ получения гамма-l-глутамилгистамина, применение гамма-l-глутамилгистамина, фармацевтическая композиция
CA2371514C (en) Adsorption and removal of endotoxin from physiological fluids using cationic helix peptides
WO1990011766A1 (en) Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
KR100294245B1 (ko) 계피로부터 분리한 시남 알데하이드 유도체의 신규한 용도

Legal Events

Date Code Title Description
PC Transfer

Free format text: AVENTIS PHARMA DEUSTSCHLAND GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS. QUANTO A REIVINDICACAO 3, RESSALVA-SE O DISPOSTO DO ARTIGO 10 VIII DA LPI 9279/96.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.